PeP-Tronic Medical

PeP-Tronic Medical is a clinical-stage biotechnology company based in Hamburg, Germany, specializing in the development of targeted peptide-based therapeutics for oncology and inflammatory diseases. The company's core technology platform focuses on the creation of peptide-drug conjugates (PDCs) that utilize specific ligands to deliver cytotoxic agents directly to cells overexpressing receptors like the gonadotropin-releasing hormone receptor. Its lead candidate, PT-101, is designed for the treatment of advanced prostate cancer, aiming to provide a more targeted and less toxic alternative to traditional chemotherapy. Beyond its lead program, PeP-Tronic is advancing a pipeline that includes PT-102 for breast cancer and other candidates for inflammatory conditions. The company was founded as a spin-off from the University of Tübingen and continues to leverage its expertise in peptide chemistry to address significant unmet needs in hormone-dependent cancers.